or search on
|Title:||Menopausal Hormone Therapy use and breast cancer risk in Australia: Findings from the New South Wales Cancer Lifestyle and EvAluation of Risk (CLEAR) study|
|Authors:||Salagame U; Banks E; Sitas F; Canfell K|
|Categories:||Cancer Type - Breast Cancer|
Etiology - Exogenous Factors in the Origin and Cause of Cancer
|Journal Title:||International Journal of Cancer|
|Abstract:||Randomised controlled trials and large scale observational studies have found that current use of Menopausal Hormone Therapy (MHT) is associated with an increased risk of breast cancer; this risk is higher for oestrogen-progestagen combination therapy than for oestrogen only therapy. The current study was designed to estimate MHT-associated breast cancer risk in a population of Australian women. Data were analysed for postmenopausal women with self-reported incident invasive breast cancer (n=1,236) and cancer-free controls (n=862), recruited between 2006 and 2014 into a large case-control study for all cancer types, the NSW CLEAR study. Information on past and current MHT use was collected from all participants, along with other lifestyle and demographic factors, using a self-administered questionnaire. Unmatched multivariable logistic regression was performed, adjusting for socio-demographic, reproductive and health behaviour variables, body mass index and breast screening history. Compared to never-users of MHT, the adjusted odds ratio (aOR) for breast cancer in current users of any type of MHT was 2.09(95%CI: 1.57-2.78; p<0.0001) and for past users of any type of MHT the aOR was 1.03(0.82-1.28; p=0.8243). For current users of oestrogen-only and oestrogen-progestagen therapy, aORs were 1.80(1.21-2.68; p=0.0039) and 2.62(1.56-4.38; p=0.0003), respectively. These findings are consistent with those from other international observational studies, that current, but not past, use of MHT is associated with a substantially increased risk of breast cancer. This article is protected by copyright. All rights reserved.|
|Division:||Cancer Research Division|
|Funding Body:||Karen Canfell and Emily Banks receive salary support from the National Health and Medical Research Council of Australia|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.